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Abstract 
 
Introduction: 
Systemic lupus erythematosus (SLE) is a rare multisystem autoimmune disease 
which occurs most severely in young females of African descent. Life expectancy is 
reduced, either directly due to the disease itself or related comorbidities.  
Aim of study: 
To determine the prevalence and spectrum of comorbidities in patients with SLE 
attending the Chris Hani Baragwanath Academic Hospital (CHBAH) Lupus Clinic. 
Patients and Methods: 
A retrospective record review of 200 SLE patients attending the CHBAH Lupus Clinic 
for at least 6 months. Data collected included demographics, clinical and serological 
evidence of SLE, autoantibody status, treatment modalities and comorbid conditions. 
The Charlson Comorbidity Index was used to measure the total comorbidity burden. 
 
Results: 
The majority of patients were black females (94%) with a mean age (SD) of 34.6 
years (11). Disease duration and American College of Rheumatology (ACR) criteria 
fulfilled were 7 years and 5 respectively. The median (IQ range) CCI was 1 (0-3). 
Baseline and cumulative prevalence of one or more comorbidities was 36.5% (95% 
CI: 29.8-43.6%), and 56.0% (95% CI: 48.8-63.0%), respectively. The most frequent 
comorbidities were hypertension (HPT) (43.5%), severe infections (29%), 
tuberculosis (TB) (15%), and HIV infection (9%). Univariate risk factors for serious 
infection were the number of ACR criteria fulfilled and leucopaenia, while both 
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univariate and multivariate risk factors were anti-Sm antibodies, thrombocytopaenia 
and the use of immunosuppressive drugs.  Risk factors for HPT included age at 
onset, disease duration, CNS involvement and chloroquine use. Risk factors for TB 
were disease duration and the use of azathioprine. Protective factors were age of 
onset, arthritis as a clinical criteria and hypocomplementaemia. 
 
Conclusion: 
In this study of predominantly black females, comorbidities were common but the 
spectrum differs to those reported in industrialised, Western countries. Infections, 
both those requiring hospitalisation for intravenous antibiotics, and TB, were amongst 
the commonest comorbidities, relating to risk factors such as the use of 
immunosuppressive drugs, autoantibody status and disease duration. Furthermore, 
despite the high prevalence of HPT, cardiovascular comorbidities were very rare. 
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Chapter 1:  
1.1 Introduction  
 
Systemic lupus erythematosus (SLE) is a rare multisystem autoimmune disease, 
occurring most commonly and severely in young females of African descent in the 
South African setting. (Tikly and Navarra, 2008). It results from a multifactorial 
interplay between genetics and the environment (Tikly and Navarra, 2008). 
 
"I have lupus, but lupus doesn't have me.‖ This simple statement by Nick Cannon, an 
entertainer and television celebrity suffering from this disease, highlights how easily 
one can be defined by having lupus. 
 
The word lupus means wolf in Latin. Rogerius, an Italian physician, likened the 
erosive facial features of lupus sufferers to wounds from a wolf bite. Superstition 
prevailed in the Middle Ages and at this time, patients with lupus were associated 
with wolves because of their disfiguring disease (Mallavarapu and Grimsley, 2007).    
 
Three periods define the history of lupus – the classical, neoclassical and modern. 
During the classical period, lupus was considered purely a disorder of the skin. 
Original descriptions by Bateman and Willan, are now recognisable as lupus vulgaris, 
an ulcerative rash attributed to tuberculosis (TB), a disease that was rife during this 
period; but it was Biett and Cazenave who coined the term lupus erythematosus and 
described the typical discoid lupus rash. Around the same time, Kaposi and his 
father-in-law, Ferdinand von Hebra, described the well-known butterfly malar rash 
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(Mallavarapu and Grimsley, 2007). Kaposi further distinguished lupus vulgaris from 
lupus erythematosus. When the TB bacillus was identified, and not found in patients 
with lupus, the association between the two diseases lost favour (Mallavarapu and 
Grimsley, 2007) . 
 
The neoclassical period began when Kaposi described the systemic nature of SLE. 
Osler described a disseminated form of the disease which became known as  
systemic lupus erythematosus (Mallavarapu and Grimsley, 2007).  Klemperer‘s 
discovery of endocarditis and glomerulonephritis at autopsy led to the term collagen 
vascular disease (Mallavarapu and Grimsley, 2007).  
 
The discovery of the LE cell by Hargraves in 1948 introduced the modern period 
(Mallavarapu and Grimsley, 2007). During this time, antinuclear antibody (ANA) and 
other autoantibodies such as lupus anticoagulant (LA)  and the false positive 
Wasserman reaction (WR) test were discovered (Mallavarapu and Grimsley, 2007).  
 
In 1971, the first classification criteria for SLE was proposed which were then revised 
in 1982 by the American College of Rheumatology (ACR) (Tan et al., 1982). This 
revision included the addition of the anti-nuclear antibody test (ANA) and a total of 11 
criteria, 4 of which were needed to classify a patient as having SLE, with a minor 
revision in 1997 to include anti-phospholipid antibodies as part of the immunological 
criteria (Hochberg, 1997). In 2012, the improved clinically relevant Systemic Lupus 
International Collaborating Clinics Classification Criteria for Systemic Lupus 
Erythematosus (SLICC) classification for SLE were published (Petri et al., 2012).  
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The SLICC criteria include a wider spectrum of clinical features of lupus, especially 
with respect to the skin and neurological features, and serological features including 
C3/C4 hypocomplementaemia. In addition, patients solely having immune complex 
glomerulonephritis and a positive ANA and/or anti-dsDNA antibodies, commonly 
seen in people of African extraction, can be classified as SLE. These criteria have 
better sensitivity than the ACR criteria (Tikly and Navarra, 2008, Petri et al., 2012) 
 
The clinical course of SLE comprises periods of flares and remissions, with outcomes 
ranging from remission to death (O'Neill and Cervera, 2010). The clinical 
presentation of SLE ranges from predominantly cutaneous manifestations to life 
threatening organ involvement (O'Neill and Cervera, 2010, Tikly and Navarra, 2008). 
Risk factors for severe major organ involvement include early age of onset and 
African or Asian ancestry (Wadee et al., 2007, Tikly and Navarra, 2008).  
 
The prevalence of SLE in South Africa is estimated to be 12.2/100 000 population 
(Morrison et al., 1990). Prevalence rates range from 14.6-78.5/100 000 population in 
North America to 159/100 000 population in Puerto Rico (O'Neill and Cervera, 2010). 
Both the incidence of SLE and survival rates of patients with SLE have increased 
over the decades (Cervera et al., 1999). This improved survival, together with the 
rising use of potent drugs including corticosteroids (CS) and immunosuppressive 
agents, has led to increased recognition of comorbidities (Cervera et al., 1999). Early 
recognition of those patients at risk of comorbid conditions is important to 
determining a preventative management strategy (Morrison et al., 1990). 
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Despite the improvement in both the treatment of SLE and survival rates, the 
outcomes in South Africans is poorer than in industrialised countries (Wadee et al., 
2007). The spectrum of comorbidities found in South Africans also differs to those 
seen in the industrialised, Western world (Tikly and Navarra, 2008).  Moreover, SLE 
may mimic or be mimicked by a range of comorbid conditions, especially HIV in the 
South African setting (O'Neill and Cervera, 2010). 
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1.2 Literature Review 
 
Although SLE occurs globally, several studies suggest that the disease is more 
severe in people of African descent; survival rates are lower and the mean age of 
onset is earlier (Gabriel and Michaud, 2009, Lau et al., 2006, Wadee et al., 2007, 
Fernandez et al., 2007).  In industrialised, Western white populations, 5-year survival 
rates are in excess of 95%, with infection and thrombotic events being the most 
common causes of death (Cervera et al., 1999). In contrast, the 5-year survival rate 
in Black South Africans has been estimated to be 72%, at best. Mortality in SLE may 
be due to disease activity, treatment or comorbid conditions (Tikly and Navarra, 
2008, Bernatsky et al., 2006) 
 
Mortality in patients with SLE in industrialised countries has a bimodal distribution. 
Early deaths are mainly caused by infection and disease activity and beyond five 
years, death is mainly attributed to malignancy and cardiovascular disease (CVD) 
(Abu-Shakra et al., 1995).  In South Africa, this bimodal distribution is not as 
apparent and the majority of deaths arise from infection, renal involvement and 
disease activity (Tikly and Navarra, 2008). Mortality from CVD and malignancy seen 
in industrialised countries does not account for late deaths in South African SLE 
patients (Wadee et al., 2007). These differences are multifactorial and include 
genetic factors, disease severity and socioeconomic disparities (Tikly and Navarra, 
2008). 
 
Numerous studies in various populations have shown that comorbidities are common 
in SLE, but the spectrum varies in different populations. In industrialised, Western 
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populations, CVD is the commonest comorbidity followed by infections (27%), 
hypertension (11.3%), osteoporosis (OP) (7.5%), Type 2 diabetes mellitus (DM) 
(2.7%) and malignancies (0.7%). Less common are gastrointestinal bleeds, 
cataracts, avascular necrosis of joints (AVN) and retinopathy (Cervera et al., 1999). 
Data from a Puerto Rican study, exhibited similar findings, with some comorbidities 
occurring more commonly in older age groups. Hypertension (HPT), DM, coronary 
artery disease (CAD) and OP featured prominently in the older group of patients. In 
addition, hypothyroidism and end stage renal disease (ESRD) were seen irrespective 
of age in 19% and 2.1% of the study population respectively (Molina et al., 2007). In 
the Taiwanese, sepsis is the leading cause for acute morbidity (42.1%) and 
nephropathy the commonest chronic comorbidity (35.1%) (Kang et al., 2012). In 
developing countries, including South Africa, infections are a frequent comorbidity. 
Many patients have lupus nephritis as part of their initial diagnostic criteria (Tikly and 
Navarra, 2008, Wadee et al., 2007) .  
 
Cardiovascular disease is the leading cause of morbidity and mortality in SLE 
patients in Western countries, with coronary artery events being up to fifty-fold higher 
than the general population in the 35 – 44 year age group (Fangtham and Petri, 
2013). The risk for CVD was 2.66 times higher in patients with SLE when compared 
to the Framingham general population (Fangtham and Petri, 2013).  Inflammation 
associated with SLE is an independent risk factor for CVD, and in combination with 
traditional CV risk factors, predisposes to premature atherosclerosis (Fangtham and 
Petri, 2013, Duran et al., 2007, Thorburn and Ward, 2003). Cardiovascular morbidity, 
a common cause for hospitalisation of SLE patients, encompasses a diverse range of 
diseases such as acute myocardial infarction (MI), congestive cardiac failure (CCF), 
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cerebrovascular accidents (CVA) and other thrombotic events (Thorburn and Ward, 
2003). As many as 3–15% of SLE patients in American studies experienced  non-
fatal CVAs or  strokes, with an overall  20% increase in stroke risk (Thorburn and 
Ward, 2003, Pyrpasopoulou et al., 2012).  
 
The metabolic syndrome (MetS) has been found to be more common in young 
patients with SLE, with a prevalence of 18-32%, which is higher in comparison to 
controls (Thorburn and Ward, 2003).  Obesity itself is independently associated with 
inflammation and impaired functional capacity (Oeser et al., 2005). Predictors of the 
MetS include CS dose, older age, ethnicity, renal involvement and use of 
immunosuppression (Thorburn and Ward, 2003). 
 
Osteoporosis, which increases the risk of bone fractures, is common in SLE patients. 
The reasons are multiple and include CS use, inactivity, chronic inflammation, renal 
involvement and vitamin D deficiency (Garcia-Carrasco et al., 2009). A South African 
study has shown that SLE itself causes trabecular bone loss which is independent of 
CS use (Kalla et al., 1993). Numerous studies have shown reduced bone mineral 
density (BMD) in SLE patients and the prevalence of OP varying between 3 - 42%. 
Furthermore, in one study, 42% of SLE patients had a history of at least one 
symptomatic bone fracture; a 50-70% increase compared to population controls 
(Oeser et al., 2005).  
 
Comorbid infections are attributed to both the underlying disease and therapy 
thereof. They occur throughout the course of SLE, often irrespective of disease 
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activity. The most common sites of infection found in Mexican studies were the 
genitourinary tract, skin, lung and musculoskeletal systems (Zonana-Nacach et al., 
2001). The majority of these infections were bacterial (42%), and most were minor, 
not requiring hospitalisation. Susceptibility to infection varied depending on disease 
activity, steroid use, renal involvement and hospitalisation (Zonana-Nacach et al., 
2001).  
 
The incidence of tuberculosis (TB) in SLE patients is up to seven fold higher than in 
the general population, with immunocompromised patients having a higher risk of 
extra-pulmonary TB (Hodkinson et al., 2009). Risk factors for developing TB include 
black ethnicity, central nervous system involvement (CNS), lymphopaenia, 
hypocomplementaemia and CS use (Hodkinson et al., 2009). The majority of patients 
who developed TB were diagnosed within the first two years of their SLE diagnosis. 
The spectrum of TB differs in SLE patients, with extensive pulmonary disease, 
disseminated disease and a high relapse rate more commonly seen than in patients 
with TB but without SLE.(Hodkinson et al., 2009). 
 
Although HIV is an uncommon comorbid infection, it poses both a therapeutic and 
diagnostic challenge in those patients who are infected. In one study, patients with 
coexisting HIV and SLE, 54.7% were diagnosed with HIV prior to the diagnosis of 
SLE and 75.5% had SLE remission with HIV progression. SLE flares were seen after 
the initiation of antiretroviral drugs and an increase in viral load was seen following 
cyclophosphamide as a treatment modality (Carugati et al., 2013). HIV and SLE have 
several clinical features in common and HIV is a cause of a false positive ANA (Tager 
and Tikly, 1999). 
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Malignancies are an important comorbidity, seen more commonly in industrialised 
countries (Turesson and Matteson, 2013). Both haematological and solid organ 
tumours are more common in SLE patients compared to the general population, 
varying between 3.2-11.4% (Sultan et al., 2000, Liang et al., 2012). Risk factors 
include inflammation, oncogene overexpression, viruses, longer disease duration and 
certain treatment modalities, such as cytotoxic agents (Turesson and Matteson, 
2013). The risk of cancer in SLE patients appears to be higher in those below 40 
years of age and the risk decreases with age (Chen et al., 2010). Chronic activation 
of B and T cells in autoimmune diseases is thought to, in part, cause 
lymphoproliferative malignancy (Turesson and Matteson, 2013). Abnormal pap 
smears seen in SLE patients are associated with an increase in the risk of cervical 
cancer, 3.5 fold compared to the general population (Bernatsky et al., 2012). 
 
Psychological comorbidities such as mood, panic and anxiety disorders are common 
in female patients with SLE. In one study, 47% of the study sample had a major 
depressive disorder (Bachen et al., 2009). In cohort studies in the Taiwanese 
population, elderly male SLE patients have shown a higher risk of developing chronic 
obstructive pulmonary disease. However, smoking was an important confounder 
(Shen et al., 2014). Patients with SLE may have an increase in hearing and 
vestibular disorders with many of these patients suffering from recurrent headaches 
and migraines (Batuecas-Caletrio et al., 2013). 
 
Treatment options for SLE have advanced over the years. The modalities of 
treatment may either cause or exacerbate comorbid conditions (Fangtham and Petri, 
2013). Corticosteroids (prednisone), even at a low dose have been associated with 
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infection, cardiovascular events, DM and OP (Hodkinson et al., 2009). All of the 
immunosuppressive agents predispose to cytopaenias, malignancy and infection, 
especially herpes zoster (Cervera et al., 1999, Fangtham and Petri, 2013). 
 
Morbidity and mortality may be attributed to either SLE itself or to comorbid 
conditions. Scoring systems give each condition a weight thereby morphing it into a 
single score that can be measured against an outcome (Jonsen et al., 2011).  
Although many comorbidity scores have been tried, the Charlson Comorbidity Index 
(CCI) has been validated in many studies and is most widely used (Charlson et al., 
1987). Developed in 1984, it predicts ten year mortality by calculating a score based 
on age and range of clinical conditions that increase mortality. The CCI is used to 
predict prognosis in patients with multiple cumulative comorbid conditions (Charlson 
et al., 1987) .  The CCI has been used in studies looking at renal disease, liver 
disease and malignancy (Romero-Diaz et al., 2011).  However, one of its 
shortcomings in the context of SLE is that the CCI does not include comorbidities like 
HPT and infection which are frequently seen in SLE patients. The CCI does however 
incorporate 17 common comorbidities, giving different weighting to mild and severe 
disease (Romero-Diaz et al., 2011).   A number of disease activity scores are used in 
clinical practice such as the SLE disease activity index (SLEDAI) and the SLICC/ACR 
damage index which measures cumulative major organ damage irrespective of 
whether this is disease or drug related (Petri et al., 2012).  
 
A number of studies using the CCI have been conducted in various countries. In 
Ireland, the CCI was used on several occasions to identify CVS comorbidities in 
various rheumatologic diseases (Mohammad et al., 2010).  This study concluded that 
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these comorbidities impact on treatment as well as complications (Mohammad et al., 
2010). A Swedish study utilising the CCI, found that in patients with SLE, comorbidity 
was an independent indicator for decreased survival (Jonsen et al., 2011). The CCI 
was an independent factor of hospital mortality in an Asian study (Yang et al., 2014). 
An American study concluded that comorbid conditions can arise from the disease 
itself or be due to unrelated factors such as age and pathways common to both SLE 
and the comorbid condition (Wolfe et al., 2010).  Certain conditions found in the CCI 
were highlighted in this study, especially cardiovascular events, gastrointestinal 
disease and diabetes (Wolfe et al., 2010). An American study, looking at short term 
predictors of mortality, concluded that the CCI itself is an important predictor and can 
be used for individual prognosis (Ward et al., 2006). The CCI has also been used as 
a variable in comparing cohorts of different ages, being worse in the older-onset 
group (Lalani et al., 2010). 
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1.3 Aim and objectives 
 
In the context of SLE in SA, there have been a few studies that have focused on 
causes of hospitalization and death (Wadee et al., 2007), but to date none that have 
specific focus on comorbidities in SLE.  
 
The aim of this study was to investigate comorbidities in South African patients with 
SLE. 
 
Primary objective 
 The prevalence and spectrum of comorbidities in South Africans with SLE 
Secondary objectives 
 Using the common comorbidities found in the CCI to identify comorbidities in 
our study population 
 Identifying common comorbidities not included in the CCI 
 Predictors of comorbidity 
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Chapter 2: Patients and Methods 
 
2.1 Study design 
 
Retrospective case record review 
 
2.1.1  Patient Inclusion Criteria 
 
A retrospective case record review of case records of patients attending the Chris 
Hani Baragwanath Academic Hospital Connective Tissue Diseases Clinic and 
fulfilling the following inclusion and exclusion criteria 
Inclusion criteria 
1. Age ≥16 years at diagnosis  
2. Fulfilled 1997 ACR classification criteria for SLE  
3. Follow up period of at least 6 months  
4. Actively attending clinic as at 31 May 2015 
Exclusion Criteria  
1. No clinical evidence of an overlap connective tissue syndrome 
2. Deceased patients 
2.1.2  Data abstraction 
 
 The following data were abstracted from the case records:  
a. Demographics 
 Age of disease onset, defined as the age when diagnosis of SLE was 
confirmed either at the Lupus Clinic, or by a referring specialist physician. 
 Gender 
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 Ethnicity 
 Disease duration, calculated as at time from diagnosis to last follow up visit. 
b. Clinical and serological evidence of SLE as per 1997 ACR criteria (Appendix A). 
These criteria were assessed at the time of first diagnosis (baseline) and during the 
course of follow up (cumulative frequency). Autoantibody status, including anti-
dsDNA, anti-Sm, anti -Ro, anti-La, anti-cardiolipin (IgG and IgM) antibodies, lupus 
anticoagulant and C3/C4 hypocomplementaemia were documented. In the case of 
patients with lupus nephritis, the renal biopsy results were reported according to the 
ISN classification. 
c. The CCI (Appendix B), and other comorbidities not found in the CCI, including 
HPT, serious infection, TB, OP and avascular necrosis (AVN) of joints.  Hypertension 
was defined as a blood pressure of greater than 140/90mmHg on at least three 
occasions or those patients on antihypertensive treatment. Serious infection was 
defined as infections necessitating hospitalisation and the use of intravenous 
antibiotic therapy. The diagnosis of TB was based on microbiological evidence or 
strong clinical and radiological suggestion. Osteoporosis as defined by a bone 
density scan with a T-score of less than -2.5 or patients with a documented diagnosis 
of osteoporosis and patients on treatment for osteoporosis. Malignancy as further 
defined in the CCI. Avascular necrosis as determined by imaging studies (plain 
radiography or MRI). 
 
d. Drug Therapy 
1. Prednisone in varying doses 
2. Immunosuppressive drugs including chloroquine, methotrexate, azathioprine, 
mycophenolate mofetil, cyclophosphamide, rituximab and other. 
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The data was documented as either ever, never or current. High dose prednisone 
defined as an intravenous steroid pulse or an oral dose of 1mg/kg or more. Low 
dose defined as an oral dose of less than 7.5mg per day. 
2.2  Sample size and statistical analysis 
 
Data was captured using a data capture sheet and was transcribed onto an Excel 
spreadsheet.  When descriptive statistics were parametric, means and standard 
deviation was used, whereas non-parametric, or skewed data was reported using 
medians and interquartile range. Categorical data was analysed using the chi-
squared test and the Mann Whitney test was used to analyse data that was not 
normally distributed. The variables were compared to comorbidities at baseline and 
during the course of disease.  A p-value of <0.05 was deemed to be significant.  
When multivariate log-binomial regression was used, a p<0.20 in the univariate 
regressions were selected (Daniel, 1998, Peduzzi et al., 1996).  
 
2.3 Ethical approval 
 
This study was approved by the Human Research Ethics Committee (Medical), 
clearance certificate number M140979. 
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Chapter 3: Results 
 
The majority of patients in this cohort of 200 patients were black female (94%, 94% 
respectively). The mean age (SD) was 34.6 (11) years with the median duration (IQ 
range) of disease being 7 years (3.25-12). 
 
The median number of ACR criteria at presentation was 5 whereas during the course 
of disease, the median criteria fulfilled were 6. The cumulative frequency of ACR 
criteria and antibody status is shown in Table 3.1. Of the patients who had renal 
involvement, 46.4% had lupus nephritis class V, 21% class III and 11% class IV. 
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Table 3.1  Demographic data, clinical features of SLE and autoantibodies 
Variable Cumulative frequency n (%) 
Age of onset  in years, mean  (SD) 34.6 (11) 
Duration of disease in years, median  7 (3.25-12) 
Gender:  female 188 (94) 
Ethnicity  
   Black 188 (9.4) 
   Indian 10 (5) 
  White 2 (1) 
ACR criteria  
   Malar rash   90 (45) 
   Discoid rash  91 (45.5) 
   Oral ulcers  64 (32) 
   Photosensitivity  82 (41) 
   Arthritis  148 (74) 
   Serositis  41 (20.5) 
   Renal disorder  86 (43) 
   Neurologic disorder  32 (16) 
   Haemolytic anaemia 19 (9.5) 
   Thrombocytopaenia  36 (18) 
   Leucopaenia  92 (46) 
   Lymphopaenia  61 (30.5) 
   Immunologic disorder  160 (80) 
   Antinuclear antibody (ANA)  199 (99.5) 
Autoantibodies  
   Anti-dsDNA antibody  76 (38) 
   Anti-Sm antibody  115 (57.5) 
   Anti-Ro antibody  105 (52.5) 
   Anti-La Antibody  53 (26.5) 
   C3/C4 hypocomplementaemia  108 (54) 
   IgG anti-cardiolipin Antibody IgG  50 (25) 
   Anti-cardiolipin Antibody IgM 42 (21) 
   Lupus Anticoagulant  10 (5) 
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Figure 3.1  Frequency of SLE Features 
 
 
 
 
Figure 3.2 Frequency of Autoantibodies and hypocomplementaemia 
 
 
 
 
0,0%
10,0%
20,0%
30,0%
40,0%
50,0%
60,0%
70,0%
80,0%
90,0%
100,0%
During course
Initally
0,00%
10,00%
20,00%
30,00%
40,00%
50,00%
60,00%
70,00%
80,00%
90,00%
100,00%
During course
Initially
19 
 
Immunosuppressive therapy 
 
Table 3.2 Immunosuppressive Agent 
 
Immunosuppressant agent  Cumulative frequency n (%) 
Prednisone (all strengths) 173 (86.5) 
Chloroquine  195 (97.5) 
Azathioprine  64 (32) 
Methotrexate  68 (34) 
Cyclophosphamide 40 (20) 
Mycophenolate mofetil  48 (24) 
 
 
 
 
 
Figure 3.3 Use of Immunosuppressive Agents 
 
 
 
0,0%
10,0%
20,0%
30,0%
40,0%
50,0%
60,0%
70,0%
80,0%
90,0%
100,0%
current
ever
20 
 
Comorbidities 
 
The prevalence of one or more comorbidities at initial presentation was 36.5% (95% 
CI: 29.8-43.6%) increasing to 56.0% (95% CI: 48.8-63.0%) by the end of the follow 
up period. The median (IQ range) Charlson comorbidity score was 1 (0-3).  One third 
of patients with TB had extra-pulmonary TB, and of the patients who had serious 
infection, one third had multiple infections during the course of their disease.  The 
spectrum of comorbidities are shown in Table 3.3. The connective tissue diseases 
referred to in the data were either secondary antiphospholipid syndrome or 
secondary Sjogrens syndrome. Overlap conditions were an exclusion criteria.  
 
 
 
 
Figure 3.4 Frequency of Comorbidities 
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Table 3.3 Spectrum of Comorbidities 
 
Comorbidity Cumulative frequency n (%) 
Comorbidities in the CCI  
   Myocardial infarction    3 (1.5) 
   Congestive cardiac failure  4 (2) 
   Peripheral vascular disease 1(0.5) 
   Cerebrovascular disease  3 (1.5) 
   Chronic obstructive pulmonary disease 5 (2.5) 
   Connective tissue disease    31 (15.5) 
   Peptic ulcer disease    17 (8.5) 
   Diabetes mellitus uncomplicated  9 (4.5) 
   Diabetes mellitus complicated   2 (1) 
   Chronic kidney disease     15 (7.5) 
   Hemiplegia      2 (1) 
   Solid tumour localized    5 (2.5) 
   Mild liver disease     6 (3) 
   Moderate/severe liver disease   1 (0.5) 
   AIDS/HIV  19 (9.5)  
Added Comorbidities  
   Hypertension  87 (43.5) 
   Severe infection     58 (29) 
   Tuberculosis     30 (15) 
   Osteoporosis     6/14 (42.8) 
   Avascular necrosis    5 (2.5) 
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Predictors of comorbidities 
 
Predictors of comorbidity are shown in Tables 3.4 and 3.5. 
 
In patients who initially presented with serious infection, risk factors included the 
presence of Anti-Ro antibodies and the use of MMF. 
 
For those patients that had HPT at presentation, univariate risk factors included age 
at onset and renal involvement.  Protective factors included fewer number of ACR 
criteria both initially and cumulatively, as well as the use of low dose prednisone.  
Multivariate risk factors included age of onset, renal involvement and the use of 
rituximab. Protective factors were use of low dose prednisone and the number of 
ACR criteria. 
 
Table 3.4 Comorbidities at initial presentation 
 
Comorbidity Risk factor  Univariate OR 
(95 %CI) 
Multivariate OR    
(95% CI) 
Severe infection Presence of Anti-Ro 
antibodies 
3.4 (3.2-9.2)  
 MMF use 3.6 (1.4-9.1)  
    
Hypertension Age of onset 1.05 (1.02-1.07) 1.08 (1.04-1.13) 
 Renal disorder 2.0   (1.2-3.4) 4.4   (1.8-10.5) 
 Initial no ACR criteria  0.86 (0.53-0.86) 0.62 (0.43-0.90) 
 Total no ACR criteria  0.62 (0.49-0.80) 0.53 (0.37-0.77) 
 Use of low dose 
prednisone  
0.5   (0.29-0.86) 0.46 (0.21-0.99) 
 Use of rituximab  17    (1.7-172) 
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Table 3.5 Cumulative Comorbidities 
Comorbidity Cumulative risk factors Univariate OR (95 
% CI) 
Multivariate OR 
(95 % CI) 
Severe infection No. ACR Criteria 1.25 (1.09-1.44)  
 Anti Sm-antibody 1.75 (1.1-2.7) 1.9 (1.03 – 3.4) 
 High dose prednisone use 1.6 (1.1 – 2.5)  
 Cyclophosphamide use 1.6 (1.03-2.6) 2.2 (1.2 – 3.9) 
 Methotrexate use 1.7 (1.04-2.8)  
 Thrombocytopaenia 1.9 (1.07-3.3 2.2 (1.2-3.9) 
    
Hypertension Age of onset 1.03 (1.02-1.04) 1.02 (1.01-1.03) 
 Duration of disease 1.03 (1-1.05) 1.05 (1.02-1.09) 
 Chloroquine use 1.5 (1.1-2.1)  
 Total no ACR criteria  0.79 (0.65-0.96)  
 Renal disorder   1.4 (1.1-2.0) 1.2 (1.04-1.4) 
 CNS involvement 1.6 (1.1-2.3)  
 Presence of anti- cardiolipin IgG 0.43 (0.22-0.84) 0.66 (0.45-0.99) 
 Methotrexate  use 1.9 (1.2-3.2) 1.8 (1.1-3.0) 
 Leukopaenia 1.9 (1.09-3.2)  
    
Tuberculosis Use of Azathioprine 2.1 (1.1-4.0)  
 Duration of disease 1.14 (1.07-1.22) 1.16 (1.08-1.25) 
 Presence of anti-Ro antibodies 0.43 (0.19-0.94)  
 Hypocomplementaemia 0.27 (0.11-0.63) 0.19 (0.07-0.56) 
 Age of onset  0.95 (0.90-0.99) 
 Presence of arthritis  0.29 (0.10-0.81) 
    
Connective Tissue 
Disease 
Presence of Anti Ds-DNA 2.8 (1.2-6.8)  
 Presence of  Anti-cardiolipin IgG 2.7 (1.2-6.3)  
 Presence of  Anti-cardiolipin IgM 2.7 (1.2-6.4) 2.8 (1.3-5.8) 
 Presence of Lupus 
Anticoagulant  
3.6 (1.2-10.3)  
 Presence of anti-sm antibodies 0.2 (0.07-0.57) 0.20 (0.07-0.58) 
 Use of cyclophosphamide 2.9 (1.3-6.7) 2.8 (1.3-5.9) 
    
Peptic Ulcer Disease  Duration of disease 1.11 (1.05-1.19)  
    
Chronic Kidney 
Disease 
Use of chloroquine 3.3 (1.2-8.8)  
 Use of cyclophosphamide 3.7 (1.4-9.7)  
 Renal involvement 5.8 (1.9-17.7)  
    
HIV Presence of lupus anticoagulant 3.8 (1.1-12.9)  
 Use of chloroquine 2.4 (1.03-5.7)  
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Cumulative Comorbidity 
 
Serious infection 
Univariate predictors included total number of ACR criteria, the presence of Anti-Sm 
antibodies, the presence of thrombocytopaenia and leukopaenia and the use of high 
dose of prednisone, cyclophosphamide, methotrexate and MMF. Multivariate 
predictors included the use of both MMF and cyclophosphamide, the presence of 
anti-sm antibodies and the presence of thrombocytopaenia. 
 
Hypertension 
Univariate predictors included age at onset, duration of disease, the use of 
chloroquine, CNS and renal involvement. Protective predictors included the number 
of criteria and the presence of Anti-Cardiolipin IgG antibodies.  
 
Tuberculosis 
Univariate predictors included the use of azathioprine and the duration of disease. 
Protective predictors included hypocomplementaemia and the presence of anti-Ro 
antibodies. Multivariate predictors were duration of disease whereas protective 
predictors were age of onset, hypocomplementaemia and the presence of arthritis. 
 
Connective Tissue Disease 
 
Univariate predictors included the presence of Anti-DsDNA , anti-cardiolipin IgG 
antibodies, anti-cardiolipin IgM antibodies and lupus anticoagulant as well as the use 
of cyclophosphamide. The presence of anti-Sm antibodies was protective for CTD. 
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Multivariate predictors were the use of cyclophosphamide and the presence of anti-
cardiolipin IgM antibodies. Once again, anti-Sm antibodies were protective. 
 
Peptic ulcer disease 
Duration of disease was a predictor for the development of PUD 
 
Chronic kidney disease 
The use of chloroquine and cyclophosphamide were predictive of CKD. Renal 
involvement  was a risk factor for CKD. 
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Chapter 4: Discussion 
 
In this study cohort of predominantly black females with SLE, just over one third of 
patients had one or more comorbidities at diagnosis, and this figure rose to almost 
60% after a mean follow up of approximately 7 years.   
 
The frequency of clinical features in our study is similar to that seen in other South 
African studies (Wadee et al., 2007, Dubula and Mody, 2015).  As the majority of 
early deaths in SLE is reported to occur within five years of diagnosis, the median 
duration of our study was adequate to study comorbidities in this population (Wadee 
et al., 2007).  
 
South Africa is a country with a heterogeneous population of 54.96 million people 
(Statistics South Africa, 2015), with elements of both first and third world populations. 
Chris Hani Baragwanath Hospital has access to all the tests and facilities required to 
make a diagnosis of SLE, most of which are not available in rural Africa (Tikly and 
Navarra, 2008).  Systemic lupus erythematosus is uncommon in rural tropical Africa 
and it has been proposed that infections such as malaria may be protective against 
SLE (Tikly and Navarra, 2008). SLE predominantly affects with theories suggesting a 
role for both oestrogen and the X chromosome. Genetic susceptibility is shown by 
monozygotic twins having  higher concordance rates and family clustering of cases 
(O'Neill and Cervera, 2010). 
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The spectrum of diseases in South Africans with SLE differs significantly to that 
found in developed countries. The most notable difference between our patient 
population and that of the developed world is the high burden of serious infection, TB 
and HPT and the low burden of both malignancy and CVD (Wadee et al., 2007, 
Dubula and Mody, 2015). Black SLE patients have more severe disease with 
increased mortality. This may be due to increased comorbidity, socio-economic 
status, environmental and genetic factors (Bernatsky et al., 2006).  Of note, certain 
comorbidities may be transient. Peptic ulcer disease is a potentially curable condition 
and steroid related comorbidities may improve with discontinuation of the medication. 
 
Previous studies have focused on mortality in SLE patients but none have looked 
specifically at the spectrum of comorbidities. Both the disease itself and treatment 
thereof contribute to mortality in SLE patients (Cervera et al., 1999). Improved 
survival rates of SLE sufferers, will impact on future development of comorbidities. In 
this study, mortality was not the focus.  European studies have shown that mortality 
in SLE patients is higher than that in age and sex matched controls. Predictors of 
mortality were female sex, younger age, a shorter duration of disease and black race 
(Bernatsky et al., 2006). This fits the demographics of our study population. Previous 
mortality studies of South African patients with SLE showed that the majority of 
deaths were attributable to infection (45%) and renal failure (16.4%) with the minority 
being caused by cardiovascular events (Wadee et al., 2007). In contrast, mortality in 
European studies revealed an event rate of 3.8, 4.1, 1.5 and 0,6 per 1000 person-
years for active disease, cardiovascular events, malignancy and infection 
respectively (Bernatsky et al., 2006). 
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South Africa is an endemic TB area with an incidence of 450 000 cases of active TB 
in 2013 (Kanabus, 2016).  As of 2013, TB was the leading cause of death in South 
Africa (Kanabus, 2016). Up to 80% of South Africans are infected with TB, the 
majority of who have latent TB infection. The highest prevalence of latent TB is found 
in young adults living in townships - areas designated during Apartheid for black 
South Africans (Kanabus, 2016).  Patients with SLE are already 
immunocompromised and therefore at higher risk for TB.  A study conducted in 
Durban, South Africa showed that 12% of hospital admissions in SLE patients with 
infections, were from TB (Dubula and Mody, 2015). This is comparable to the 15% 
seen in this study. In keeping with other studies, one third of patients had extra-
pulmonary TB, however lymphopaenia was not found to be predictive of TB, unlike 
prior reports (Hodkinson et al., 2009). Lymphopaenia, with a frequency of 30.5% in 
our study, is seen in up to 50% of African patients (Tikly and Navarra, 2008).  
Predictors of TB shown in a previous South African study included black ethnicity, 
lymphopaenia, C3/C4 hypocomplementaemia, CNS involvement, corticosteroid use 
and use of immunosuppressive drugs. Multivariate analysis showed that independent 
risk factors were lymphopaenia, corticosteroid use and duration of corticosteroid 
treatment (Hodkinson et al., 2009). Despite the high background prevalence of TB, 
isoniazid prophylaxis was issued to only 2.2% patients in the above mentioned study 
(Hodkinson et al., 2009). In comparison, this current study analysis showed the use 
of azathioprine and the duration of disease were predictors of TB. Conversely, an 
older age of onset, presumably with less drug exposure was protective. Longer 
duration of SLE and the use of immunosuppressants, was associated with a greater 
risk of TB. Patients who are older at diagnosis and who have milder disease have 
lower TB rates, probably related to less exposure to prednisone and other 
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immunosuppressants. Hypocomplementaemia and the presence of anti-Ro 
antibodies were also protective.  
 
The cumulative frequency of severe infection was 29% in this study. This is a high 
burden of infection, especially considering that one third of subjects had multiple 
infections. A study in a similar population group in Durban, concluded that 35.2% and 
17.7% of admissions were for infections and a combination of infection and active 
disease respectively (Dubula and Mody, 2015). Of these admissions, 14.4% died 
from severe infections, including TB, pneumonia, urinary tract infections and soft 
tissue infections (Dubula and Mody, 2015).  Predictors of severe infection in the 
abovementioned study were greater number of ACR criteria met, auto-antibody 
status, immunosuppressant use and more severe SLE. In comparison, this current 
study showed that in addition to the number of ACR criteria, auto-antibody status and 
immunosuppressant use, thrombocytopaenia and leukopaenia are also predictors for 
serious infection.  Infections are the main contributor to morbidity and mortality in 
developing countries and the susceptibility arises from both the disease itself and the 
treatment thereof. Often, there is not ready availability of costly supportive health 
care services such as intensive care units, which impacts on both morbidity and 
mortality (Bernatsky et al., 2006). Furthermore, our patients are not able to access 
hospital care in a timeous manner, and this delay in treatment results in more 
advanced, complicated disease presentations. 
 
South Africa has a high prevalence of HPT. In 2010, the estimated prevalence was 
over 40% in those older than 25 years (Statistics South Africa, 2015).  This is similar 
to the cumulative frequency of 43.7% in the study population. Those patients with 
renal involvement were more likely to either have HPT at diagnosis or develop it 
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during the course of disease. Other predictors of hypertension were older age of 
onset and CNS involvement. Patients who had fewer ACR criteria without renal 
involvement, and who required lower doses of prednisone were unlikely to have HPT.  
Despite the high cumulative frequency of HPT, the cardiovascular comorbidities seen 
in industrialised countries were not evident in this study which probably reflects the 
demographics of the young female study population. Previous European studies 
showed an 11.3% frequency of HPT, well below that seen in the current study. Renal 
involvement in the same group of patients was only 22.2%; despite the relatively low 
frequency of HPT and renal involvement, almost a quarter of mortality was from 
cardiovascular events (Cervera et al., 1999).  
 
 
The secondary connective tissue diseases seen in this study included Sjogrens 
syndrome and Anti-Phospholipid Syndrome (APS). Anti-Sm antibodies are specific 
for SLE and patients with this auto-antibody therefore do not have secondary CTD. 
Patients with anticardiolipin antibodies often have APS and are often sicker and 
require the use of powerful immunosuppressants such as cyclophosphamide.  
 
This study found that those patients with CKD were more likely to be on highly potent 
immunosuppressive drugs, whilst lupus nephritis was causally related to CKD. 
 
Malignancy, especially haematological cancers are one of the more common 
comorbidities seen in developed countries. In this study, no patients had 
haematological malignancies, and the only solid tumours seen were Kaposi sarcoma 
(KS) in one HIV positive patient and local cervical cancer. This may reflect the young 
age of the patient population and a relatively short follow up time. As both KS and 
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cancer of the cervix are AIDS defining illnesses, the spectrum of malignancy 
highlights the burden of HIV in our community. In American studies, a 2-3 fold 
increase in non Hodgkin‘s lymphoma is seen with a standardised mortality ratio of 2.8 
in comparison with controls (Bernatsky et al., 2012). Theories for the increase in 
haematological malignancies include translocation of oncogenes, the immune 
system‘s ability to promote oncogenesis and chronic inflammation which alters the 
immune system (Bernatsky et al., 2012).   
 
The Soweto population is changing. What was once a relatively rural community, 
named in 1963 and formed to accommodate black residents from rural areas, has 
now transformed into a more urban community. This change has brought with it an 
increase in non-communicable diseases such as diabetes and CVD. Although this 
urbanisation has advantages in terms of socio-economic empowerment, it brings with 
it a ―triple threat‖ of CVD as shown in the Heart of Soweto Study (Sliwa et al., 2008). 
The morbidity from cardiovascular disease is caused by HIV, infectious diseases and 
now from the more traditional cardiovascular risk factors. In the future, the bimodal 
pattern of mortality seen in first world nations may also apply to the South African 
population. This study however failed to show the cardiovascular morbidity shown in 
overseas studies. 
 
The CCI is one of the tools used to predict mortality based on a range of 
comorbidities. Most of our patients had a low CCI score, with the most common 
comorbidities being those conditions not included in the original score such as HPT 
and severe infection. The CCI has been extensively validated in many studies for a 
range of conditions. It has also compared favourably to other indices, however in our 
population group it was not as useful as anticipated due to the extremely low 
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prevalence of both cardiovascular events and malignancies. First world studies report 
a higher prevalence of these diseases and the CCI would better predict mortality in 
these populations. In a Swedish study, the CCI score was an independent risk factor 
for mortality in SLE patients and  demonstrated a direct relationship between 
comorbidities and mortality in SLE (Jonsen et al., 2011). 
 
One of the major complications of SLE is organ dysfunction, which impacts on 
morbidity and mortality (Ruiz-Irastorza et al., 2012). Previous studies looking at 
causes for hospitalisation showed that infections, renal failure and the disease itself 
accounted for the majority of admissions (Thorburn and Ward, 2003). Patients with 
more severe SLE, as evidenced by renal and neurological manifestations, are treated 
with more potent immunosuppression. This does not come without risks. It was found 
that cyclophosphamide use increased both the risk of lymphoma and bladder cancer 
(Bernatsky et al., 2012, Ruiz-Irastorza et al., 2012). This highlights the complexities 
associated with selecting an appropriate treatment modality, whilst considering the 
risk-benefit profile.  
 
 
Corticosteroids are commonly used in the treatment of SLE. This study showed that 
86.5% of the cohort used steroids as part of the treatment regime. Although the use 
of immunosuppressive agents has increased survival, they come with their own 
complications and may cause organ dysfunction  and impact on quality of life 
(Garcia-Carrasco et al., 2009, Ruiz-Irastorza et al., 2012). Corticosteroid use itself 
can cause or contribute to a number of serious comorbidities included in this study. 
Osteoporosis, DM, AVN and HPT can occur as a direct consequence of long term 
steroid use. Moreover, corticosteroid use can augment the existing increased risk of 
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infection and malignancy associated with SLE (Bernatsky et al., 2012, Dubula and 
Mody, 2015). The cumulative dose and duration of steroid treatment impacts on 
complications; with long term use of high doses associated with greater morbidity 
(Ruiz-Irastorza et al., 2012).  The frequency of OP and AVN was very low in this 
study. This may be underestimated, as a consequence of a lack of screening for 
these conditions. In this study population, very few patients had bone densitometry 
scans, despite being on corticosteroid therapy for prolonged periods of time. 
 
Approximately four million people in South Africa (11.2% of the total population) are 
HIV positive, with the highest incidence in females of reproductive age (Statistics 
South Africa, 2015). Systemic lupus erythematosus predominantly affects young 
females in the same age group, however the frequency of HIV in this population is 
lower compared to that in the general South African population (Tikly and Navarra, 
2008).  The cumulative frequency of HIV was 9.5% in our study population – well 
below the 25% found in the same age group in the general population (Statistics 
South Africa, 2015). This may reflect the health behavior of SLE patients or the 
interplay between the two disease entities.  Patients with concurrent HIV at SLE 
diagnosis, or who contracted HIV during the course of their disease seem to have 
milder disease with fewer complications (Mody et al., 2014).  Problems arise when 
trying to distinguish the symptoms of HIV and SLE as both may have similar 
manifestations (Tikly and Navarra, 2008, Mody et al., 2014). Apart from the clinical 
overlap, autoantibodies may be falsely positive in HIV positive patients and false 
positive HIV results may occur in SLE patients (Mody et al., 2014). The number of 
ACR criteria fulfilled by HIV positive SLE patients is higher. Whether this is due to 
SLE itself or the overlapping features of both diseases remains unclear (Mody et al., 
2014). The biggest problem arises with treatment of the HIV positive SLE patient. A 
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low CD4 count from HIV is protective of autoimmune diseases but the potent 
immunosuppressants used for the treatment of SLE may worsen the symptoms of 
HIV (Mody et al., 2014). HIV needs to be routinely screened for in the South African 
SLE population as early diagnosis and treatment with readily available highly active 
anti-retroviral agents (HAART) can prevent both opportunistic infections and 
complications of HIV (Mody et al., 2014). 
 
Limitations of the study include a relatively small sample size of 200 patients. As with 
any retrospective study, information was abstracted from case records, which may 
not have been complete. As screening for each comorbidity on the CCI is not done 
routinely, patients may have a comorbidity that is not recorded in the case files. 
Some patients may have received treatment for conditions other than lupus from 
other specialist clinics which may not have been recorded. Height and weight was 
not consistently documented in the files and therefore BMI could not be calculated. 
Obesity is an important morbidity in developed countries, which not only impairs 
functional capacity, but also increases inflammation (Oeser et al., 2005).  Screening 
for malignancy was not documented in the files. Since the malignancy found most 
commonly in this relatively young female study population was localized cervical 
cancer, perhaps the human papilloma virus vaccine should be offered as part of 
preventative care. As most patients are on corticosteroid therapy, objective evidence 
of OP and AVN should be sought. 
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Chapter 5: Conclusion 
 
In this study of predominantly black females, comorbidities were common but the 
spectrum differs to those reported in industrialised, Western countries. There is a 
high burden of comorbidities in South African SLE patients,  with the prevalence of 
one or more comorbidities during the course of the disease being 56.0% (95% CI: 
48.8-63.0%).   
 
Most notable is a high prevalence of HPT and severe infections, including acute 
infections requiring hospitalisation and intravenous antibiotic use, as well as TB.  The 
results suggest that SLE patients with higher disease burden (more ACR criteria and 
immunologic markers) are more likely to develop severe infections. Furthermore, 
younger patients, with more severe disease, requiring more potent 
immunosuppressive drugs, are at increased risk for TB.  
 
Cardiovascular complications, a major comorbidity reported in industrialised, Western 
countries, were rare in this study, despite a high prevalence of HPT. Malignancies 
seen in patients in industrialised countries were also not evident in this population. 
Osteoporosis and AVN were uncommon comorbidities, reflecting the lack of 
screening for such conditions. 
 
―I'm tired of having to struggle for what seems to come easily to everyone else‖, said 
Mercedes Lackey. This statement about living with chronic illness holds true for those 
suffering from SLE. Systemic lupus erythematosus, its treatment and comorbidities, 
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all contribute to an overall poor quality of life for those afflicted. One hope for the 
future is that identifying predictors of comorbidities might lead to their prevention.  
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Chapter 7: Appendices 
Appendix A: ACR Criteria for SLE 
 
The 1997 Update of the 1982 American College of Rheumatology Revised Criteria 
for Classification of Systemic Lupus Erythematosus 
Criteria Definition 
1. Malar rash Fixed erythema, flat or raised, over the malar eminences, 
tending to spare the nasolabial folds  
2. Discoid rash Erythematous raised patches with adherent keratotic scaling 
and follicular plugging; atrophic scarring may occur in older 
lesions  
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by 
patient history or physician observation  
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless, 
observed by physician  
5.Nonerosive Arthritis Involving 2 or more peripheral joints, characterized by 
tenderness, swelling, or effusion  
6. Serositis a) Pleuritis—convincing history of pleuritic pain or rubbing 
heard by a physician or evidence of pleural effusion  
OR  
b) Pericarditis—documented by ECG or rub or evidence of 
pericardial effusion  
7. Renal disorder a) Persistent proteinuria greater than 0.5 grams per day or 
greater than 3+ if quantitation not performed  
OR  
b) Cellular casts—may be red cell, haemoglobin, granular, 
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tubular, or mixed  
8. Neurologic 
disorder 
a) Seizures—in the absence of offending drugs or known 
metabolic derangements; e.g., uremia, ketoacidosis, or 
electrolyte imbalance  
OR  
b) Psychosis—in the absence of offending drugs or known 
metabolic derangements, e.g., uremia, ketoacidosis, or 
electrolyte imbalance  
9. Haematologic 
disorder 
a) Haemolytic anaemia—with reticulocytosis  
OR  
b) Leukopenia—less than 4,000/mm  on 2 or more occasions  
OR  
c) Lymphopenia—less than 1,500/mm on 2 or more 
occasions  
OR  
d) Thrombocytopenia—less than 100,000/mm  in the 
absence of offending drugs  
10. Immunologic 
disorder 
a) Anti-DNA: antibody to native DNA in abnormal titer  
OR  
b) Anti-Sm: presence of antibody to Sm nuclear antigen  
OR  
c) Positive finding of antiphospholipid antibodies on: 
 An abnormal serum level of IgG or IgM anticardiolipin 
antibodies 
 A positive test result for lupus anticoagulant using a 
standard method 
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 A false positive test for at least 6 months confirmed 
by Treponema pallidum immobilisation or fluorescent 
treponemal antibody absorption test 
11. Antinuclear 
antibody 
An abnormal titre of antinuclear antibody by 
immunofluorescence or an equivalent assay at any point in 
time and in the absence of drugs known to be associated 
with ―drug-induced lupus‖ syndrome  
 
* The proposed classification is based on 11 criteria. For the purpose of identifying 
patients in clinical studies, a person shall be said to have systemic lupus 
erythematosus if any 4 or more of the 11 criteria are present, serially or 
simultaneously, during any interval of observation.  
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Appendix B: Charlson Comorbidity Index 
 
Scoring: Comorbidity Component (Apply 1 point to each unless otherwise noted) 
1. Myocardial Infarction  
2. Congestive Heart Failure 
3. Peripheral Vascular Disease  
4. Cerebrovascular Disease  
5. Dementia 
6. COPD 
7. Connective Tissue Disease 
8. Peptic Ulcer Disease 
9. Diabetes Mellitus (1 point uncomplicated, 2 points if complicated) 
10. Moderate to Severe Chronic Kidney Disease (2 points) 
11. Hemiplegia (2 points) 
12. Leukemia – acute or chronic (2 points) 
13. Malignant Lymphoma (2 points) 
14. Solid Tumor (2 points, 6 points if metastatic) 
15. Liver Disease (1 point mild, 3 points if moderate to severe)  
16. AIDS/HIV (6 points) 
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Scoring: Age 
1. Age <40 years: 0 points 
2. Age 41‐50 years: 1 points 
3. Age 51‐60 years: 2 points 
4. Age 61‐70 years: 3 points 
5. Age 71‐80 years: 4 points 
Interpretation 
1. Calculate Charlson Score or Index (i) 
2. Add Comorbidity score to age score 
3. Total denoted as ‗i‘ below 
 
Calculate Charlson Probability (10 year mortality) 
1. Calculate Y = e^(i * 0.9) 
2. Calculate Z = 0.983^Y 
3. where Z is the 10 year survival  
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Appendix C: Ethics Certificate 
